Amarin Announces Completion of Offering of American Depositary Shares

Amarin Announces Completion of Offering of American Depositary Shares

Amarin Received Net Proceeds of $5.60 per ADS

BEDMINSTER, N.J. and DUBLIN, Ireland, July 12, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN) ("Amarin" or the "Company") today announced that
it had completed its previously announced underwritten public offering of
21,700,000 American Depositary Shares ("ADSs"). The underwriters purchased the
ADSs from Amarin at a price of $5.60 per ADS, resulting in net proceeds to
Amarin of approximately $121.1 million, after deducting estimated offering
expenses payable by Amarin.Amarin has also granted the underwriters a 30-day
option to purchase an additional 3,255,000 ADSs.Amarin intends to use the net
proceeds from this offering primarily to continue the commercial launch of
Vascepa® (icosapent ethyl) capsules in the MARINE indication, prepare for and
commercially launch Vascepa in the ANCHOR indication, if approved, advance the
Company's REDUCE-IT cardiovascular outcomes trial, and for general corporate
and working capital purposes.

Citigroup Global Markets Inc. and Jefferies LLC acted as joint book-running
managers and underwriters in this offering.

A registration statement relating to the ADSs described above was previously
filed with and has become effective by rule of the Securities and Exchange
Commission (the "SEC"). A final prospectus supplement relating to the offering
has been filed with the SEC and is available on the SEC's website at
http://www.sec.gov. Copies of the final prospectus supplement and related
prospectus may be obtained from Citigroup, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, email:
batprospectusdept@citi.com, telephone 1-800-831-9146; and Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th
Floor, New York, New York, 10022, telephone: 877-547-6340, email:
Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

AboutAmarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health.

Disclosure Notice

This press release contains forward-looking statements, within the meaning of
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Statements that are not historical facts, including statements related
to the Company's public offering of American Depositary Shares and use of
proceeds are forward-looking statements that involve risks and uncertainties.
These forward-looking statements are not promises or guarantees. These
forward-looking statements are based upon the Company's current expectations.
Actual events and results and the timing of events and results could differ
materially from those anticipated in such forward-looking statements.Among
the factors that could cause actual results to differ materially from those
described or projected herein are the following: risks related to the
underwriter's consummation of their obligation to purchase the securities,
risks associated with market conditions and the satisfaction of customary
closing conditions related to the proposed offering, as well as the risks,
uncertainties and other matters detailed in Amarin's filings with the SEC,
including its most recent Quarterly Report on Form 10-Q for the period ending
March 31, 2013, its Registration Statement on Form S-3 filed with the SEC on
March 29, 2011, and the final prospectus supplement. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date they were made. The Company
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise, except as required by law.

CONTACT: Investor Contact Information:
        
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (860) 572-4979 x292
         investor.relations@amarincorp.com

company logo